Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan R Shuldiner

Showing results (11-20 of 404) with videos related to

Pageof 41
Sort By:
Journal of Human Genetics|May 24, 2013
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Christina G Perry, Alan R Shuldiner
Current Diabetes Reports|March 20, 2003
The role of peroxisome proliferator-activated receptor gamma in diabetes and obesityFrancesco S Celi, Alan R Shuldiner
Human Genetics|April 28, 2022
Pharmacogenomics: the low-hanging fruit in the personalized medicine treeGeorge P Patrinos, Alan R Shuldiner
Current Diabetes Reports|March 30, 2005
Does bariatric surgery reduce obesity-related comorbidities?Richard B Horenstein, Alan R Shuldiner
Lancet (London, England)|January 9, 2003
Physical activity and prevention of type 2 diabetesSoren Snitker, Braxton D Mitchell, Alan R Shuldiner
Endocrinology and Metabolism Clinics of North America|January 9, 2004
The genetics of obesityColeen M Damcott, Paul Sack, Alan R Shuldiner
The Journal of Clinical Endocrinology and Metabolism|May 6, 2004
Hepatic lipase genotype, diabetes risk, and implications for preventative medicineAlan R Shuldiner, Nicole Hoppman, Toni I Pollin
JAMA|April 13, 2012
CYP2C19 genotype and cardiovascular eventsAlan R Shuldiner, Mark R Vesely, Adam Fisch
The New England Journal of Medicine|December 14, 2016
Variants in ANGPTL4 and the Risk of Coronary Artery DiseaseFrederick E Dewey, Jesper Gromada, Alan R Shuldiner
Circulation|October 6, 2010
Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement"Paul A Gurbel, Udaya S Tantry, Alan R Shuldiner
Pageof 41

Showing results (11-20 of 404) with videos related to

Sort By:
Pageof 41
Journal of Human Genetics|May 24, 2013
Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Christina G Perry, Alan R Shuldiner
Current Diabetes Reports|March 20, 2003
The role of peroxisome proliferator-activated receptor gamma in diabetes and obesityFrancesco S Celi, Alan R Shuldiner
Human Genetics|April 28, 2022
Pharmacogenomics: the low-hanging fruit in the personalized medicine treeGeorge P Patrinos, Alan R Shuldiner
Current Diabetes Reports|March 30, 2005
Does bariatric surgery reduce obesity-related comorbidities?Richard B Horenstein, Alan R Shuldiner
Lancet (London, England)|January 9, 2003
Physical activity and prevention of type 2 diabetesSoren Snitker, Braxton D Mitchell, Alan R Shuldiner
Endocrinology and Metabolism Clinics of North America|January 9, 2004
The genetics of obesityColeen M Damcott, Paul Sack, Alan R Shuldiner
The Journal of Clinical Endocrinology and Metabolism|May 6, 2004
Hepatic lipase genotype, diabetes risk, and implications for preventative medicineAlan R Shuldiner, Nicole Hoppman, Toni I Pollin
JAMA|April 13, 2012
CYP2C19 genotype and cardiovascular eventsAlan R Shuldiner, Mark R Vesely, Adam Fisch
The New England Journal of Medicine|December 14, 2016
Variants in ANGPTL4 and the Risk of Coronary Artery DiseaseFrederick E Dewey, Jesper Gromada, Alan R Shuldiner
Circulation|October 6, 2010
Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement"Paul A Gurbel, Udaya S Tantry, Alan R Shuldiner
Pageof 41